Evolution of oncology
Since FTI research in early 2000 and late 1990, companies have been using a broader pool of cell lines.
So, less true that about in vivo and in vitro vs. human non correlation.
Variance is due to simplistic extrapolation from a few unrepresentative results to overall population.
Genomics now fills out the gap.
Good point about not a RAS inhibitor but a GTP protein inhibitor.
4601 is a GTP protein, competitor imo. 4601 is also a competitor to Rho. End result is still inhibition.
GTP proteins are akin to building blocks for signalling pathway. Too much of em make the signal stronger.
Exposure to 4601 stop that reaction for a while, long enough for cell to stop replicating and to see apoptosis.
Playing around with GTP protein is a good idea.
Raf-1 and K-ras seem to be hallmark of GBM as indicated in this article
https://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2373912
GTP protein interference fits with cancer genome atlas finding.